Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide

Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide

The FDA has released a guide aimed at accelerating drug development through the use of AI in clinical trials. This article outlines key takeaways and implications for pharmaceutical teams. For business development executives and biopharma investors tracking regulatory catalysts, the agency's formal request for information signals a watershed moment in the marriage of machine learning and clinical evidence generation—one that will reshape deal flow, partnership structures, and trial design strategies through the back half of this decade.

Key Takeaways

First, the FDA's RFI puts a hard regulatory stake in the ground: AI isn't a science project anymore—it's a legitimate tool for mitigating clinical trial failures, and the agency wants structured input on how to govern it. Second, the Center for Drug Evaluation and Research has already logged more than 300 drug and biologic submissions incorporating AI components, a data point that caught the attention of every regulatory affairs head in the industry. Third, the guide lays out best practices that will become de facto compliance benchmarks, meaning BD teams evaluating AI-native biotechs or platform acquisitions now have a clearer due diligence framework than they did six months ago.

What the FDA Published—and Why It Matters Now

On May 1, 2026, the FDA's Center for Drug Evaluation and Research published its long-awaited guiding principles on artificial intelligence in drug development. The document, which sits alongside the agency's broader "Artificial Intelligence for Drug Development" resource page, isn't a binding regulation—it's a request for information paired with a set of principles the agency expects sponsors to internalize. But in Washington, RFIs frequently preview binding guidance, and smart regulatory teams treat them accordingly.

"FDA recognizes the increased use of AI throughout the drug development process and across a range of therapeutic areas," the agency stated flatly on its CDER landing page, a signal that the era of ad hoc AI submissions is ending. The RFI specifically probes how machine learning models can improve patient selection, optimize dosing regimens, and flag safety signals earlier—areas where Phase II and Phase III attrition has bedeviled sponsors for decades. More than 300 submissions incorporating AI components have already crossed CDER's desks, a volume that forced the agency's hand on formalizing its stance.

The guide arrives at a moment when big pharma R&D organizations are quietly embedding AI into their discovery and development workflows. Scientists from companies including Pfizer, Novartis, and Roche have been using predictive models to identify potential safety red flags before compounds enter the clinic, a practice that was once considered experimental and is now becoming standard operating procedure. The FDA's RFI effectively asks industry to show its work: what algorithms are you using, how are they validated, and what happens when the model drifts?

The EMA, meanwhile, has been running a parallel track through its own AI working groups, and the two agencies have been coordinating behind the scenes. Sponsors hoping to file in both jurisdictions should assume their AI-driven trial designs will face aligned—though not identical—scrutiny. The harmonization push is real, but gaps remain on data provenance standards and model interpretability requirements.

What This Means for BD and Regulatory Teams

For business development groups, the RFI transforms AI from a buzzword into a quantifiable asset class. When a biotech claims its platform uses "proprietary AI" to de-risk clinical development, acquirers and partners now have a regulatory framework against which to test that assertion. The questions practically write themselves: Has the model been trained on datasets that meet FDA's expectations for diversity and representativeness? Does the algorithm's output feed directly into dose-selection decisions? If the model fails, what's the human override protocol?

Regulatory affairs teams inside pharma companies are already dissecting the FDA's language around model validation and real-world performance monitoring. The agency's emphasis on "Good AI Practice"—a deliberate echo of Good Clinical Practice—suggests that inspectional standards are coming. Companies that build AI governance into their quality management systems now will have first-mover advantage when formal guidance lands. Those that bolt it on later will pay in delay.

The competitive implications are stark. Sponsors who can credibly demonstrate that their AI tools reduced screen-failure rates or shortened enrollment timelines will find an easier path through regulatory review—and a warmer reception from investors. Private equity groups and venture arms that have been circling AI-enabled CROs and trial analytics firms now have a clearer thesis: the FDA just told the industry what it wants, and the companies that deliver it fastest will capture outsized value.

FAQ

What is the purpose of the FDA's AI clinical trials RFI?
The RFI aims to gather structured information from sponsors, technology vendors, and other stakeholders on how artificial intelligence can improve clinical trial efficiency and reduce the stubbornly high failure rates that drive up drug development costs. The agency wants to understand current practices before issuing binding guidance.

How can pharmaceutical companies benefit from this guidance?
Companies can align their AI strategies with the regulatory expectations the FDA has now made explicit, potentially compressing drug development timelines and avoiding costly mid-trial surprises. For BD teams, the RFI provides a due diligence lens for evaluating acquisition targets and licensing opportunities that lean heavily on machine learning claims.

Where can I find more information on the FDA's AI initiatives?
The FDA maintains a dedicated "Artificial Intelligence for Drug Development" page on its CDER website at fda.gov. The agency's external engagements and public workshops are catalogued on that page. The EMA's emerging AI framework can be tracked through its Innovation Task Force updates.

What should investors watch for next?
The FDA's analysis of RFI responses will likely surface in a public workshop or discussion paper within the next 12 to 18 months. In the interim, every new drug application or biologics license application that references AI-driven analyses will serve as a test case for the agency's evolving thinking. Track the CDER AI submissions count—it went from zero to 300-plus in roughly five years, and the slope of that curve will tell you how fast the regulatory apparatus is adapting.

Related coverage

• Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts
• GLP-1 usage statistics show broad uptake and mixed clinical signals
• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain